Personal Information
Entreprise/Lieu de travail
Greater Boston Area, Massachusetts United States
Profession
Principal, Larchmont Strategic Advisors - reimbursement strategy counsel to companies across the life sciences spectrum
Site Web
www.larchmontstrategic.com
À propos
Ed Berger has more than 25 years of experience working in senior management or as a consultant with medical device, biotechnology and health services companies, dealing with reimbursement issues and other problems at the intersection of U.S. and international health care policy, corporate strategy development, and strategically sensitive corporate communications with government, investors and the media. In 2005, Ed founded Larchmont Strategic Advisors to help life sciences companies create and implement integrated strategies to address the obstacles and opportunities they face in their efforts to secure public and private insurer coverage and optimal reimbursement for new or evolving tec...
Mots-clés
agel investors
funding opportunities
health care reform
reimbursement
comparative effectiveness research
Tout plus
Présentations
(5)Personal Information
Entreprise/Lieu de travail
Greater Boston Area, Massachusetts United States
Profession
Principal, Larchmont Strategic Advisors - reimbursement strategy counsel to companies across the life sciences spectrum
Site Web
www.larchmontstrategic.com
À propos
Ed Berger has more than 25 years of experience working in senior management or as a consultant with medical device, biotechnology and health services companies, dealing with reimbursement issues and other problems at the intersection of U.S. and international health care policy, corporate strategy development, and strategically sensitive corporate communications with government, investors and the media. In 2005, Ed founded Larchmont Strategic Advisors to help life sciences companies create and implement integrated strategies to address the obstacles and opportunities they face in their efforts to secure public and private insurer coverage and optimal reimbursement for new or evolving tec...
Mots-clés
agel investors
funding opportunities
health care reform
reimbursement
comparative effectiveness research
Tout plus